Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free NKGN Stock Alerts

NKGen Biotech (NKGN) Competitors

NKGen Biotech logo
$0.0051 0.00 (0.00%)
As of 08/13/2026
Compare

NKGN vs. CASI, CANF, SXTC, CDT, and BPTH

Should you buy NKGen Biotech stock or one of its competitors? NKGen Biotech's main competitors and comparable companies include CASI Pharmaceuticals (CASI), Can-Fite BioPharma (CANF), China SXT Pharmaceuticals (SXTC), CDT Equity (CDT), and Bio-Path (BPTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does NKGen Biotech compare to CASI Pharmaceuticals?

NKGen Biotech (NYSE:NKGN) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

CASI Pharmaceuticals has higher revenue and earnings than NKGen Biotech. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
CASI Pharmaceuticals$26.85M0.10-$39.26M-$3.01N/A

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
CASI Pharmaceuticals Neutral

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by company insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CASI Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CASI Pharmaceuticals is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CASI Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

NKGen Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

NKGen Biotech has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
CASI Pharmaceuticals -183.93%N/A -131.54%

Summary

CASI Pharmaceuticals beats NKGen Biotech on 8 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to Can-Fite BioPharma?

Can-Fite BioPharma (NYSE:CANF) and NKGen Biotech (NYSE:NKGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

Company Net Margins Return on Equity Return on Assets
Can-Fite BioPharmaN/A N/A N/A
NKGen Biotech N/A N/A -479.36%

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Can-Fite BioPharma had 1 more articles in the media than NKGen Biotech. MarketBeat recorded 1 mentions for Can-Fite BioPharma and 0 mentions for NKGen Biotech. Can-Fite BioPharma's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
Can-Fite BioPharma Neutral
NKGen Biotech Neutral

Can-Fite BioPharma currently has a consensus target price of $44.00, suggesting a potential upside of 1,194.12%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than NKGen Biotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Can-Fite BioPharma
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Can-Fite BioPharma has higher revenue and earnings than NKGen Biotech. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can-Fite BioPharma$405K5.50-$7.63M-$22.80N/A
NKGen BiotechN/AN/A-$82.94M-$1.68N/A

Can-Fite BioPharma has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Summary

Can-Fite BioPharma beats NKGen Biotech on 8 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to China SXT Pharmaceuticals?

NKGen Biotech (NYSE:NKGN) and China SXT Pharmaceuticals (NASDAQ:SXTC) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.

NKGen Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, China SXT Pharmaceuticals has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

In the previous week, China SXT Pharmaceuticals had 4 more articles in the media than NKGen Biotech. MarketBeat recorded 4 mentions for China SXT Pharmaceuticals and 0 mentions for NKGen Biotech. China SXT Pharmaceuticals' average media sentiment score of 0.71 beat NKGen Biotech's score of 0.00 indicating that China SXT Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
NKGen Biotech Neutral
China SXT Pharmaceuticals Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
China SXT Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 5.0% of China SXT Pharmaceuticals shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 4.0% of China SXT Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
China SXT Pharmaceuticals N/A N/A N/A

China SXT Pharmaceuticals has higher revenue and earnings than NKGen Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
China SXT Pharmaceuticals$1.14M1.82-$6.20MN/AN/A

Summary

China SXT Pharmaceuticals beats NKGen Biotech on 7 of the 9 factors compared between the two stocks.

How does NKGen Biotech compare to CDT Equity?

NKGen Biotech (NYSE:NKGN) and CDT Equity (NASDAQ:CDT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 3.3% of CDT Equity shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by insiders. Comparatively, 10.8% of CDT Equity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NKGen Biotech is trading at a lower price-to-earnings ratio than CDT Equity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
CDT EquityN/AN/A-$39.22M-$14.27 thousandN/A

In the previous week, CDT Equity had 3 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for CDT Equity and 0 mentions for NKGen Biotech. CDT Equity's average media sentiment score of 0.99 beat NKGen Biotech's score of 0.00 indicating that CDT Equity is being referred to more favorably in the news media.

Company Overall Sentiment
NKGen Biotech Neutral
CDT Equity Positive

NKGen Biotech's return on equity of 0.00% beat CDT Equity's return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
CDT Equity N/A -72.25%-55.44%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NKGen Biotech
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
CDT Equity
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

NKGen Biotech has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, CDT Equity has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market.

Summary

CDT Equity beats NKGen Biotech on 8 of the 11 factors compared between the two stocks.

How does NKGen Biotech compare to Bio-Path?

NKGen Biotech (NYSE:NKGN) and Bio-Path (NASDAQ:BPTH) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

NKGen Biotech has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Bio-Path has a beta of -0.51, suggesting that its stock price is 151% less volatile than the broader market.

In the previous week, NKGen Biotech's average media sentiment score of 0.00 equaled Bio-Path'saverage media sentiment score.

Company Overall Sentiment
NKGen Biotech Neutral
Bio-Path Neutral

Bio-Path is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NKGen BiotechN/AN/A-$82.94M-$1.68N/A
Bio-PathN/AN/A-$16.08M-$1.09N/A

76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 5.7% of Bio-Path shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 0.7% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NKGen Biotech's return on equity of 0.00% beat Bio-Path's return on equity.

Company Net Margins Return on Equity Return on Assets
NKGen BiotechN/A N/A -479.36%
Bio-Path N/A -2,842.40%-337.48%

Summary

NKGen Biotech beats Bio-Path on 5 of the 8 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

Export
MetricNKGen BiotechPharmaceuticals IndustryHealthcare SectorNYSE Exchange
Market Cap$666K$11.87B$7.05B$24.33B
Dividend YieldN/A2.69%2.57%3.68%
P/E Ratio0.00775.15269.0830.78
Price / SalesN/A755.21604.1220.39
Price / CashN/A66.4570.4832.80
Price / Book0.0011.6012.916.82
Net Income-$82.94M$2.76B$3.45B$1.06B
7 Day PerformanceN/A0.08%1.10%0.54%
1 Month PerformanceN/A-0.02%1.32%2.88%
1 Year PerformanceN/A145.07%62.43%19.08%

NKGen Biotech Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
N/A$0.01
flat		N/AN/A$666KN/AN/AN/A
CASI
CASI Pharmaceuticals
N/A$0.21
flat		$4.00
+1,827.7%		N/A$2.55M$26.85MN/A180
CANF
Can-Fite BioPharma
1.4465 of 5 stars		$3.44
-3.4%		$44.00
+1,179.1%		-74.9%$2.25M$405KN/A8
SXTC
China SXT Pharmaceuticals
0.4157 of 5 stars		$0.05
-15.6%		N/A-100.0%$2.06M$1.14MN/A90
CDT
CDT Equity
1.1007 of 5 stars		$3.42
+5.9%		N/A-99.9%$2.04MN/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel